Strong Funding and Growth NephroSant has secured over $22 million in funding, indicating strong investor confidence and a solid financial foundation for expanding their innovative diagnostic solutions in the kidney transplantation space.
Innovative Technology The company's development of a low-cost, non-invasive assay for early detection of kidney injury presents a significant opportunity to sell advanced diagnostic tools to healthcare providers and transplant centers aiming to improve patient outcomes.
Market Expansion Potential With the launch of the Qsant kidney transplant rejection prediction assay and its plans to run as a laboratory-developed test at selected sites, NephroSant is positioned for strategic partnerships and sales growth in transplant clinics and medical laboratories.
Leadership and Commercialization The hiring of a chief commercialization officer reflects a focus on expanding sales and market penetration, presenting opportunities for collaboration with healthcare organizations seeking innovative transplant diagnostics.
Industry Alignment Operating within the highly specialized biotechnology research sector with a focus on kidney health, NephroSant aligns well with healthcare providers and biotech firms invested in transplant success and kidney disease management, opening avenues for strategic alliances.
NephroSant, Inc. uses 8 technology products and services including Amazon Web Services, GitHub, Docker, and more. Explore NephroSant, Inc.'s tech stack below.
| NephroSant, Inc. Email Formats | Percentage |
| FLast@nephrosant.com | 39% |
| Last@nephrosant.com | 19% |
| First@nephrosant.com | 3% |
| FLast@nephrosant.com | 39% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Kidney transplantation is the treatment of choice for patients with end-stage kidney failure. However, the life of a kidney transplant is limited due to unrecognized immune injury. There is no sensitive, non-invasive method to detect this injury at an early-stage. We have developed a reliable, inexpensive, and noninvasive assay to monitor kidney injury.
Company Overview
Media & News
Funding & FinancialsNephroSant, Inc. has raised a total of $16M of funding over 1 rounds. Their latest funding round was raised on Mar 16, 2021 in the amount of $16M.
NephroSant, Inc.'s revenue is estimated to be in the range of $1M
Funding & FinancialsNephroSant, Inc. has raised a total of $16M of funding over 1 rounds. Their latest funding round was raised on Mar 16, 2021 in the amount of $16M.
NephroSant, Inc.'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com